Blue Sky Health Sector Stock Volatility Report

Notable Movers & Volatility

The tape was sharply two-sided. MRNA led at +55.45% ($130.38 → $202.67), closing at 92.64% of its range with a +40.42% period return — and its 84.79% realized vol against 77.89% implied produced the report's biggest vol surprise at 3.40x. TEM (+49.76%, 95.26% of range) and EBS (+28.18%, 2.68x) told a similar story: options markets underpriced the actual traversal. AMGN closed nearest its high at 98.47% on a modest 28.77% implied vol (2.19x).

The opposite extreme: STIM fell -21.85% and closed at just 1.41% of range, with ADUS (1.95%) and ABT (13.00%) also finishing near their lows.

Several high-IV names never earned their premium. CDXS carried 396.09% implied vol but realized only 55.70% (0.37x) across a 15.33% range; QURE (166.97% IV, 0.62x) and HUM (86.18% IV, 0.69x) were similarly over-priced. XLV was quietest at 0.60x and 11.90% realized — the index masked enormous single-name dispersion.

Note the disconnect between range and outcome: ELV swung +9.14% yet closed at 8.72% of range with a -2.23% return.

Broader Market Context

Differential behavior within the sector. This was a dispersion event, not a sector move. XLV gained just 4.09% with 11.90% realized vol, while the underlying names spanned roughly 77 percentage points from MRNA (+55.45%) to STIM (-21.85%). Three distinct cohorts pulled apart:

• Biotech/diagnostics upside: MRNA, TEM, EBS and ADMA posted +19% to +55% ranges with realized vol running 42–85%, consistent with binary, company-specific catalysts rather than a sector bid.
• Large-cap pharma grind: AMGN (+11.90%), ABBV (+9.17%), MRK (+7.90%), GILD (+7.88%), LLY (+7.59%) and JNJ (+5.58%) all advanced on low implied vols (25–38%) and closed in the upper half of their ranges — orderly accumulation, not speculation.
• Managed care and services weakness: CVS (-13.76%), HUM (-12.11%), CNC (-12.04%), UNH (-9.97%), CI (-9.34%), THC (-8.04%) and ADUS (-7.23%) declined as a near-uniform bloc.

Rotation signals. The clean split between rising pharma and falling payors looks more like an intra-sector rotation than a whole-sector flow. Money moving *into* defensive large-cap pharma while exiting insurers and providers is consistent with investors seeking healthcare's defensive characteristics but avoiding medical-cost and reimbursement exposure. The tight clustering of the payor declines — and the fact that CNC, CVS, CI and QURE all bottomed around 09/23–09/24 — suggests a common factor rather than six independent stories. By contrast, the top gainers' extreme realized/implied ratios (3.40x, 3.17x, 2.68x) point to idiosyncratic, catalyst-driven repricing.

Plausible drivers. Without asserting specific events, the pattern is consistent with several recurring Health Sector themes:

• Policy and reimbursement uncertainty, which disproportionately affects managed care, hospitals and home-health names — the exact cohort that underperformed here.
• Clinical, regulatory or data catalysts in biotech, where pre-event implied vols were high (CDXS at 396%, QURE at 167%, HUM at 86%) yet realized moves undershot, a classic post-catalyst vol crush.
• Rate and risk-appetite shifts, which tend to amplify moves in long-duration, cash-burning small-cap biotech relative to cash-generative large-cap pharma.

The muted XLV reading is the key takeaway: index-level calm concealed unusually violent single-name behavior.